Novadip Biosciences Raises Additional Eur 40 Million Bringing Total Company Funding To Eur 88 Million
Novadip Biosciences Raises Additional Eur 40 Million Bringing Total Company Funding To Eur 88 Million
11/04/22, 3:36 AM
Location
belgiumMoney raised
€40 million
Industry
therapeutics
medical
biotechnology
health care
Novadip Biosciences (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, today announced that it has raised an additional EUR 40 million in a Series B equity round and non-dilutive funding. The funding will accelerate the clinical development of two of Novadip’s investigational adipose stem cell (ASC)-derived tissue regeneration products: NVD-X3, an allogeneic therapeutic that can provide accelerated, durable bone union in spinal fusion procedures and non-healing fractures, and NVD-003, an autologous bone engraftment product designed to provide a single treatment cure for patients with critical size bone defects such as congenital pseudoarthrosis of the tibia (CPT).
Company Info
Location
belgium
Additional Info
Novadip Biosciences is a biopharmaceutical company founded to design, develop and bring to the market innovative stem cell-based therapies for regenerative medicine. The first proprietary cellular therapy of Novadip Biosciences is a totally differentiated and 3D osteogenic scaffold-free structure which provide innovative treatments for severe bone healing disorders.
Their lead product NVD-001 introduces new principles of guided tissue regeneration based on stem cells from fatty tissue, associated to osteoinductive, osteoconductive and osteogenic properties to manufacture 3D natural bone implants with the right shape, mineralization and all mechanical properties for replacement and repair of large bone defects.
In September 2015, NOVADIP has closed EUR 28 million Series A Round with US and Belgian investors to advance his breakthrough cell therapy pipeline.